# Data Sheet (Cat.No.T40045)

TargetMol

## Sivopixant

### Chemical Properties



CAS No. : 2414285-40-6

Formula: C25H22ClN5O5

Molecular Weight: 507.93

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Sivopixant (S-600918) (S-600918) is a potent and selective antagonist of P2X3 receptor (P2X3 IC 50 =4.2 nM; P2X2/3 IC 50 =1100 nM). Sivopixant shows strong analgesic effect . |
| Targets(IC50) | P2X Receptor |
| In vivo | Sivopixant (S-600918) was identified as a clinical candidate with potent and selective antagonistic activity (P2X3 IC50, 4.2 nM; P2X2/3 IC50, 1100 nM) and a strong analgesic effect in the rat partial sciatic nerve ligation model (Seltzer model) of allodynia (ED50, 0.4 mg/kg). |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 55 mg/mL (108.28 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1.67 mg/mL (3.29 mM),Sonication is recommended.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.9688 mL | 9.8439 mL | 19.6878 mL |
| 5 mM | 0.3938 mL | 1.9688 mL | 3.9376 mL |
| 10 mM | 0.1969 mL | 0.9844 mL | 1.9688 mL |
| 50 mM | 0.0394 mL | 0.1969 mL | 0.3938 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kai H, et al. Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists [published online ahead of print, 2021 Sep 26]. Bioorg Med Chem Lett. 2021; 52:128384.

Wang D P, Zhang M, Li M, et al.Druggable site near the upper vestibule determines the high affinity and P2X3 homotrimer selectivity of Sivopixant/S-600918 and its analogue DDTPA.British Journal of Pharmacology.2023